Swimming into the future of drug discovery: in vivo chemical screens in zebrafish.
暂无分享,去创建一个
[1] Tomokazu Fukuda,et al. BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.
[2] Randall T Peterson,et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[3] C. Lindsley,et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. , 2010, ACS chemical biology.
[4] L. Zon,et al. In vivo drug discovery in the zebrafish , 2005, Nature Reviews Drug Discovery.
[5] S. Klahr. The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function. , 2003, Journal of nephrology.
[6] J. DiMasi,et al. Drug development costs when financial risk is measured using the Fama-French three-factor model. , 2009, Health economics.
[7] Calum A. MacRae,et al. Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish , 2003, Circulation.
[8] A. McMahon,et al. Genetic analysis of dorsoventral pattern formation in the zebrafish: requirement of a BMP-like ventralizing activity and its dorsal repressor. , 1996, Genes & development.
[9] L. Zon,et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis , 2007, Nature.
[10] J. Greef,et al. Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.